Oct. 29, 2002 — An Australian firm with Michigan ties will collaborate with U.S. scientists to develop nanoscale drugs that protect against biological and chemical weapons.
Pharmaceutical nanotechnology company Starpharma said subsidiary Dendritic Nanotechnologies Ltd. would receive $3.5 million from the U.S. Department of Defense. Potential projects include respiratory bioprotection and toxin-fighting agents.
Dendritic Nanotechnologies, which has labs and offices in Michigan, is a leading patent holder in pharmaceutical products from dendrimers, synthetic polymers with branching parts designed as nanoscale vehicles for delivering drugs.